FDA Approves Standalone Use of Johnson & Johnson’s Spravato for Depression
Last reviewed and updated: August 16, 2026.
Key Takeaways
| What changed | In January 2025 the FDA approved Spravato (esketamine) as a standalone monotherapy for treatment-resistant depression, the first of its kind. |
| The prior rule | Spravato was previously approved only in combination with an oral antidepressant, since its 2019 approval for treatment-resistant depression. |
| The evidence | A Phase 4 placebo-controlled trial showed esketamine alone gave rapid, superior improvement, with 22.5% in remission by week 4 versus 7.6% on placebo. |
| How it works | Spravato targets the glutamate system, unlike standard antidepressants that act on serotonin or norepinephrine, which is part of why it acts quickly. |
| The safeguards | Spravato must be given in a certified setting under a REMS program, with monitoring for sedation and dissociation and controls for abuse potential. |
In a significant development, the U.S. Food and Drug Administration has expanded the approval of Johnson & Johnson’s nasal spray, Spravato, for standalone use in treating major depressive disorder.
Find a REMS-certified Spravato clinic near you in our verified provider directory.
Previous Limitations and New Flexibility
Previously, Spravato was approved only in combination with other antidepressants for adults experiencing suicidal thoughts or actions. The new approval allows healthcare providers to personalize treatment plans based on individual patient needs.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Here’s a Timeline of Johnson & Johnson’s Spravato:
| Year | Milestone | Details and Success |
|---|---|---|
| 2019 | FDA Approval for Treatment-Resistant Depression (TRD) | Spravato was first approved as an adjunct treatment for adults with treatment-resistant depression, marking a breakthrough in addressing patients who did not respond to conventional antidepressants. |
| 2020 | Approval Expanded to Include Acute Suicidal Ideation | The FDA granted approval for use in adults experiencing suicidal thoughts or behaviors, providing a critical option for urgent care in psychiatric settings. |
| 2020 to 2024 | Adoption in Clinical Practice | Spravato gained traction among healthcare providers as a rapid-acting antidepressant. Though expensive, it demonstrated effectiveness in clinical settings for TRD and acute cases of depression. |
| 2025 | FDA Approval for Standalone Use in Major Depressive Disorder (MDD) | The FDA approved Spravato as a standalone treatment for major depressive disorder, based on clinical evidence of its efficacy compared to placebo, allowing for greater flexibility in treatment plans. |
| Ongoing | Continued Research and Global Adoption | Studies continue to explore the long-term safety and effectiveness of Spravato, while international markets adopt the treatment. The drug remains a key focus of innovation in the field of depression treatment. |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Summary of Success
- Innovative Mechanism: The drug’s novel action on glutamate receptors, rather than serotonin, offers rapid symptom relief for patients.
- Clinical Validation: FDA approvals are backed by robust studies demonstrating significant reductions in depressive symptoms, particularly in urgent cases like suicidal ideation.
- Market Impact: Despite initial cost concerns, Spravato has established itself as a vital tool in addressing severe forms of depression. Its expanding indications reflect confidence in its effectiveness and safety.
Understanding Major Depressive Disorder
Major depressive disorder is a prevalent psychiatric condition, affecting an estimated 21 million adults in the United States.
Mechanism of Action
Spravato contains esketamine, which targets the neurotransmitter glutamate. This approach differs from traditional antidepressants and offers a rapid reduction in depressive symptoms.
Clinical Evidence Supporting Approval
The FDA’s decision was based on a study demonstrating Spravato’s effectiveness in reducing the severity of depressive episodes compared to a placebo.
Implications for Treatment
This approval provides healthcare providers with greater flexibility in treating depression, allowing for more personalized and potentially effective treatment plans. The FDA’s expanded approval of Spravato marks a significant advancement in depression treatment, offering new hope for those affected by this challenging condition.
What Standalone Spravato Approval Means in 2026
On January 21, 2025, the FDA approved Spravato (esketamine) as a standalone monotherapy for adults with treatment-resistant depression. It is the first medication approved as a monotherapy for that specific condition, as Johnson & Johnson announced. Before this, Spravato was cleared only in combination with an oral antidepressant. That rule dated to its 2019 approval for treatment-resistant depression. A 2020 approval added major depressive disorder with acute suicidal ideation, again alongside an oral antidepressant.
The monotherapy approval rested on a Phase 4 randomized, placebo-controlled trial. Esketamine alone produced rapid, superior improvement on the MADRS depression scale at 4 weeks. By week 4, 22.5% of patients reached remission, compared with 7.6% on placebo. Spravato targets the glutamate system rather than serotonin or norepinephrine. That different mechanism is part of why it works quickly compared with standard antidepressants.
Standalone approval gives new options to patients who cannot tolerate or do not respond to oral antidepressants. It also simplifies treatment for many of them. Spravato still must be given in a certified healthcare setting under a REMS program. Staff monitor patients for sedation and dissociation because of its abuse and misuse potential. Compared with off-label IV ketamine, Spravato is more likely to be covered by insurance.
Frequently Asked Questions
- Can Spravato be used on its own now?
- Yes. In January 2025 the FDA approved Spravato (esketamine) as a standalone monotherapy for adults with treatment-resistant depression. It is the first medication approved as a monotherapy specifically for that condition. Previously, it had to be taken in combination with an oral antidepressant.
- How was Spravato approved before 2025?
- Spravato was first approved in 2019 for treatment-resistant depression, but only in combination with an oral antidepressant. In 2020 it was also approved, again with an oral antidepressant, for major depressive disorder with acute suicidal ideation or behavior. The 2025 approval removed the requirement to pair it with an oral antidepressant for treatment-resistant depression.
- How well does Spravato work as a monotherapy?
- In the Phase 4 trial behind the approval, esketamine used alone produced rapid, superior improvement on the MADRS depression scale at 4 weeks, with 22.5% of patients in remission by week 4 compared with 7.6% on placebo. It targets the glutamate system, which is part of why it can work faster than traditional antidepressants.
- Is Spravato safe to take, and how is it given?
- Spravato must be given in a certified healthcare setting under a REMS program, where patients are monitored for at least two hours for sedation and dissociation. These safeguards exist because of its potential for abuse and misuse. Patients cannot take it at home, and they should not drive on the day of treatment.
